Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Cigna Group (CI) delivered solid Q1 2026 results with revenue up 4.6% YoY to $68.5B and net income surging 25.0% to $1.65B, though operating cash flow declined sharply by 41.1% and cost of revenue grew faster than revenue at 11.8%.
Revenue
$68.49B
+4.57% YoY
EPS (Diluted)
$6.26
+29.07% YoY
Operating Income
$2.36B
+19.63% YoY
Source: SEC XBRL
Cigna Group (CI) reported Q1 FY2026 revenue of $68.49B, up 4.6% year over year. Operating margin was 3.4%, up 0.4 points from 3.0% a year earlier. Operating cash flow was $1.13B, down 41.1% year over year. CI's fiscal Q1 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 0 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 7.78 | 7.83 | Miss -0.6% |
| Mar 2026This filing | 7.79 | 7.84 | Miss -0.7% |
| Dec 2025 | 8.08 | 8.11 | Miss -0.4% |
| Sep 2025 | 7.83 | 7.88 | Miss -0.6% |
Adjusted (non-GAAP) EPS of $7.79 versus the $7.84 analyst consensus — a -0.7% miss for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $6.26.
Compiled by AI from this SEC filing
Total revenue increased 4.6% YoY to $68.5B in Q1 2026 from $65.5B in Q1 2025, reflecting continued expansion across Cigna's health services and pharmacy benefit management segments.
Source: 10-Q Income Statement
Net income rose 25.0% YoY to $1.65B, with diluted EPS jumping 29.1% to $6.26 from $4.85, indicating meaningful operating leverage and potentially favorable mix shifts or one-time items benefiting profitability.
Source: 10-Q Income Statement
Cost of revenue grew 11.8% YoY to $54.1B, significantly faster than the 4.6% revenue growth, compressing gross profit and suggesting rising medical costs or pharmacy benefit costs that management must manage carefully.
Source: 10-Q Income Statement
SG&A expenses declined 11.7% YoY to $3.72B from $4.21B, which helped offset cost of revenue pressures and contributed to operating income growing 19.6% to $2.36B with operating margin expanding to 3.44% from 3.01%.
Source: 10-Q Income Statement
Operating cash flow fell 41.1% YoY to $1.13B from $1.92B, and the company suspended share buybacks entirely (vs. $1.51B in Q1 2025), suggesting tighter near-term liquidity management or working capital headwinds.
Source: 10-Q Cash Flow Statement
Compiled by AI from this SEC filing · 3 high, 2 medium, 0 low
Cigna's current ratio stands at 0.82, meaning current liabilities of $52.6B exceed current assets of $43.0B. This below-1.0 ratio indicates the company may face challenges meeting short-term obligations without accessing credit facilities or generating additional cash flows.
Source: 10-Q Balance Sheet
The debt-to-equity ratio of 2.63 reflects significant financial leverage, with total liabilities of $110.8B against stockholders' equity of $42.2B. In a rising interest rate environment, this leverage level could increase financing costs and constrain strategic flexibility.
Source: 10-Q Balance Sheet
Operating cash flow dropped 41.1% YoY to $1.13B, a significant deterioration from $1.92B in Q1 2025. This decline raises questions about working capital management and whether the strong net income growth is translating into actual cash generation.
Source: 10-Q Cash Flow Statement
Cost of revenue increased 11.8% YoY versus revenue growth of only 4.6%, indicating that medical cost trends or pharmacy costs are accelerating. If this trend persists, it could materially compress margins in future quarters.
Source: 10-Q Income Statement
Cash and equivalents fell 15.5% YoY to $7.04B from $8.33B, while the company also halted share repurchases entirely. This combination suggests management is conserving cash, potentially in response to near-term financial pressures or strategic capital reallocation.
Source: 10-Q Balance Sheet & Cash Flow Statement
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 68.49 $B | 65.50 $B | +4.57% |
Cost of Revenue $B | 54.10 $B | 48.40 $B | +11.78% |
Operating Income $B | 2.36 $B | 1.97 $B | +19.63% |
Net Income $B | 1.65 $B | 1.32 $B | +25.02% |
EPS (Basic) $ | 6.30 $ | 4.88 $ | +29.10% |
EPS (Diluted) $ | 6.26 $ | 4.85 $ | +29.07% |
SG&A Expense $B | 3.72 $B | 4.21 $B | -11.65% |
Answers draw on this SEC filing and the data on this page
In Q2 FY2026, The Cigna Group delivered total revenue of $71.67B (+6.7% YoY) and net income of $1.66B (+8.4% YoY), driven by strong operating growth in Cigna Healthcare and expanding volume in Evernorth Health Services.
CI (Cigna) delivered FY2025 revenue of $274.9B (+11.2% YoY) with net income surging 73.5% to $6.0B, though operating margin compressed to 3.3% as cost of revenue grew faster than revenue.
Other companies in Health Care Services